ATP. a pioneer in life sciences venture capital, is developing the next generation of transformative biotechnology companies.
We create science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines.
We provide flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises.
We invest in our companies from seed stage through IPO and beyond, and we support our management teams in strategic transactions and synergistic business combinations.
Galaxy Medical Enrolls First Patients in SPACE-AF Study
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx™ System for Chronic Bronchitis
Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder